The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treat...

Full description

Bibliographic Details
Authors: Jimenez-Fonseca, P, Foy, V, Raby, S, Carmona-Bayonas, A, Macia-Rivas, L, Arrazubi, V, Lavin, DC, Gil, RHS, Custodio, A, Cano, JM, Montes, AF, Mirallas, O, Declara, IM, Tocino, RV, Visa, L, Limon, ML, Pimentel, P, Lago, NM, Sauri, T, Richard, MM, Mangas, M, Raga, MG, Calvo, A, Reguera, P, Granja, M, Carnicero, AM, Perez, CH, Cerda, P, Gonzalez, LG, Navalon, FG, Barcia, VP, Abad, D, Martin, MR, Weaver, J, Mansoor, W, Gallego, J
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p14965
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/14965
Access Level:Open access
Keyword:gastric cancer
HER2-positive
nomogram
oesophageal cancer
survival
trastuzumab
id ES_e04d8a80fea8a0b93be93332fc79d67a
oai_identifier_str oai:fisabio.fundanetsuite.com:p14965
network_acronym_str ES
network_name_str España
repository_id_str
spelling The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapyJimenez-Fonseca, PFoy, VRaby, SCarmona-Bayonas, AMacia-Rivas, LArrazubi, VLavin, DCGil, RHSCustodio, ACano, JMMontes, AFMirallas, ODeclara, IMTocino, RVVisa, LLimon, MLPimentel, PLago, NMSauri, TRichard, MMMangas, MRaga, MGCalvo, AReguera, PGranja, MCarnicero, AMPerez, CHCerda, PGonzalez, LGNavalon, FGBarcia, VPAbad, DMartin, MRWeaver, JMansoor, WGallego, Jgastric cancerHER2-positivenomogramoesophageal cancersurvivaltrastuzumabBackground:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Methods:Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). Results:In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. Conclusion:The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.SAGE PUBLICATIONS LTD2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/14965Therapeutic Advances in Medical OncologyISSN: 17588340ISSNe: 17588359reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p149652026-06-11T12:45:17Z
dc.title.none.fl_str_mv The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
title The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
spellingShingle The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Jimenez-Fonseca, P
gastric cancer
HER2-positive
nomogram
oesophageal cancer
survival
trastuzumab
title_short The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
title_full The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
title_fullStr The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
title_full_unstemmed The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
title_sort The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
dc.creator.none.fl_str_mv Jimenez-Fonseca, P
Foy, V
Raby, S
Carmona-Bayonas, A
Macia-Rivas, L
Arrazubi, V
Lavin, DC
Gil, RHS
Custodio, A
Cano, JM
Montes, AF
Mirallas, O
Declara, IM
Tocino, RV
Visa, L
Limon, ML
Pimentel, P
Lago, NM
Sauri, T
Richard, MM
Mangas, M
Raga, MG
Calvo, A
Reguera, P
Granja, M
Carnicero, AM
Perez, CH
Cerda, P
Gonzalez, LG
Navalon, FG
Barcia, VP
Abad, D
Martin, MR
Weaver, J
Mansoor, W
Gallego, J
author Jimenez-Fonseca, P
author_facet Jimenez-Fonseca, P
Foy, V
Raby, S
Carmona-Bayonas, A
Macia-Rivas, L
Arrazubi, V
Lavin, DC
Gil, RHS
Custodio, A
Cano, JM
Montes, AF
Mirallas, O
Declara, IM
Tocino, RV
Visa, L
Limon, ML
Pimentel, P
Lago, NM
Sauri, T
Richard, MM
Mangas, M
Raga, MG
Calvo, A
Reguera, P
Granja, M
Carnicero, AM
Perez, CH
Cerda, P
Gonzalez, LG
Navalon, FG
Barcia, VP
Abad, D
Martin, MR
Weaver, J
Mansoor, W
Gallego, J
author_role author
author2 Foy, V
Raby, S
Carmona-Bayonas, A
Macia-Rivas, L
Arrazubi, V
Lavin, DC
Gil, RHS
Custodio, A
Cano, JM
Montes, AF
Mirallas, O
Declara, IM
Tocino, RV
Visa, L
Limon, ML
Pimentel, P
Lago, NM
Sauri, T
Richard, MM
Mangas, M
Raga, MG
Calvo, A
Reguera, P
Granja, M
Carnicero, AM
Perez, CH
Cerda, P
Gonzalez, LG
Navalon, FG
Barcia, VP
Abad, D
Martin, MR
Weaver, J
Mansoor, W
Gallego, J
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv gastric cancer
HER2-positive
nomogram
oesophageal cancer
survival
trastuzumab
topic gastric cancer
HER2-positive
nomogram
oesophageal cancer
survival
trastuzumab
description Background:Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. Methods:Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK). Results:In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively. Conclusion:The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/14965
url https://fisabio.portalinvestigacion.com/publicaciones/14965
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
dc.source.none.fl_str_mv Therapeutic Advances in Medical Oncology
ISSN: 17588340
ISSNe: 17588359
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422189719060480
score 15,812429

Similar Items